ReviewKidney medicine2024
Kidney Biopsy in Management of Lupus Nephritis: A Case-Based Narrative Review.
Review in Kidney medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Factors associated with clinically significant nephritis in systemic lupus erythematosus patients who present with glomerular hematuria: a cross-sectional study.Rheumatology international · 2026Article
- Urinary Exosomes as Potential Biomarkers for Diagnosis, Disease Activity Assessment, Treatment Monitoring, and Prognosis in Lupus Nephritis.International journal of molecular sciences · 2026Review
- Screening of diagnostic biomarkers for taurine metabolism-related genes in lupus nephritis and analysis of immune infiltration.International urology and nephrology · 2026Article
- Shear wave elastography as a reliable tool in the prediction of renal histopathological abnormalities.BMC medical imaging · 2026Article
- Serum RNASE1 as a biomarker for disease activity and lupus nephritis in systemic lupus erythematosus.Frontiers in immunology · 2026Article
- Circulating long non-coding RNAs as diagnostic markers of lupus nephritis and 5-year follow-up disease flares.Frontiers in immunology · 2026Article
- New Diagnosis of Lupus Nephritis in the Third Trimester-A Case Report.Nephrology (Carlton, Vic.) · 2025Article
- When Serology Fails: Recognising Systemic Lupus Erythematosus in the Absence of Autoantibodies.European journal of case reports in internal medicine · 2025Article
- A Rare Case of Lupus Nephritis with Predominant Gastrointestinal Manifestation: A Case Study.Journal of pharmacy & bioallied sciences · 2024Article
- Urine Extracellular Vesicles Size Subsets as Lupus Nephritis Biomarkers.Diagnostics (Basel, Switzerland) · 2024Article
- Dynamics of CD4+ and CD8+ Lymphocytic Inflammatory Infiltrates in Lupus Nephritis.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney involvement in patients with lupus highly increases morbidity and mortality. In recent years, several reports have emphasized the dissociation between clinical and histological findings and highlighted the role of kidney biopsy as an instrument for diagnosis and follow-up of lupus nephritis. The kidney biopsy at initial diagnosis allows an early diagnosis, assessment of activity and chronicity, and detection of nonimmune complex nephritis. A kidney biopsy repeated months after treatment aids in the detection of persistent histological inflammation, which has been linked to the occurrence of future kidney relapses. A kidney biopsy at a relapse detects histological changes including chronic scarring. Finally, a kidney biopsy in patients with a clinical response undergoing maintenance immunosuppression may aid therapy tapering and/or suspension. The evidence supporting the use of a kidney biopsy in different scenarios across the course of lupus nephritis is heterogeneous, with most reports assessing the value for the diagnosis of a first or relapsing flare. In contrast, less evidence suggests additional therapeutic-modifying information derived from repeat posttreatment biopsies and biopsies to evaluate treatment tapering or suspension. In this clinical case-based review, we examine the role of kidney biopsy as a tool to improve clinical outcomes of patients with lupus nephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.